Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

J&J Says Ultram Titration Schedule Was Developed To Improve Safety Profile

Executive Summary

A titration dosing regimen for Johnson & Johnson's analgesic Ultram was added to the non-titrated dosing schedule in labeling in order to reduce adverse events, J&J told FDA

You may also be interested in...



Ultram Pain Indication Cannot Be Divided, J&J Says In Response To Teva

The indication for Ultram (tramadol) cannot be divided into chronic versus acute pain to justify omission of patent-protected titration dosing from generic labeling, Johnson & Johnson told FDA

Ultram Pain Indication Cannot Be Divided, J&J Says In Response To Teva

The indication for Ultram (tramadol) cannot be divided into chronic versus acute pain to justify omission of patent-protected titration dosing from generic labeling, Johnson & Johnson told FDA

Glucophage Generics Enter Market: Bristol Says It Will Not Sue Agency

Generic versions of metformin will carry labeling that refers prescribers to Bristol-Myers Squibb's Glucophage label for information on pediatric patients

Related Content

UsernamePublicRestriction

Register

PS039299

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel